Cargando…
Galactosialidosis: preclinical enzyme replacement therapy in a mouse model of the disease, a proof of concept
Galactosialidosis is a rare lysosomal storage disease caused by a congenital defect of protective protein/cathepsin A (PPCA) and secondary deficiency of neuraminidase-1 and β-galactosidase. PPCA is a lysosomal serine carboxypeptidase that functions as a chaperone for neuraminidase-1 and β-galactosid...
Autores principales: | Cadaoas, Jaclyn, Hu, Huimin, Boyle, Gabrielle, Gomero, Elida, Mosca, Rosario, Jayashankar, Kartika, Machado, Mike, Cullen, Sean, Guzman, Belle, van de Vlekkert, Diantha, Annunziata, Ida, Vellard, Michel, Kakkis, Emil, Koppaka, Vish, d’Azzo, Alessandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782203/ https://www.ncbi.nlm.nih.gov/pubmed/33426146 http://dx.doi.org/10.1016/j.omtm.2020.11.012 |
Ejemplares similares
-
AAV-mediated gene therapy for galactosialidosis: A long-term safety and efficacy study
por: Hu, Huimin, et al.
Publicado: (2021) -
Conventional and Unconventional Therapeutic Strategies for Sialidosis Type I
por: Mosca, Rosario, et al.
Publicado: (2020) -
Regulated lysosomal exocytosis mediates cancer progression
por: Machado, Eda, et al.
Publicado: (2015) -
Excessive exosome release is the pathogenic pathway linking a lysosomal deficiency to generalized fibrosis
por: van de Vlekkert, Diantha, et al.
Publicado: (2019) -
Glycosphingolipids within membrane contact sites influence their function as signaling hubs in neurodegenerative diseases
por: Weesner, Jason Andrew, et al.
Publicado: (2023)